Beat AML S8 Group 2: Gilteritinib (GILT) in combination with decitabine (DEC) and venetoclax (VEN) in untreated FLT3 mutated acute myeloid leukemia (AML) patients age ≥60 with high and low variant allele frequency (VAF) Meeting Abstract
| Authors: | Liu, Q.; Welkie, R. L.; Huang, Y.; Swords, R. T.; Lin, T. L.; Koenig, K. L.; Madanat, Y. F.; Patel, P. A.; Collins, R. H.; Blum, W.; Arellano, M.; Baer, M. R.; Stock, W.; Kovacsovics, T. J.; Olin, R.; Curran, E. K.; Stein, E. M.; Schiller, G. J.; Zeidner, J. F.; Redner, R. L.; Heerema, N. A.; Martycz, M.; Rosenberg, L.; Marcus, S. G.; Chen, T.; Stefanos, M.; Levine, R. L.; Druker, B. J.; Yocum, A. O.; Burd, A.; Mims, A.; Borate, U. M.; Byrd, J. C.; Traer, E. |
| Abstract Title: | Beat AML S8 Group 2: Gilteritinib (GILT) in combination with decitabine (DEC) and venetoclax (VEN) in untreated FLT3 mutated acute myeloid leukemia (AML) patients age ≥60 with high and low variant allele frequency (VAF) |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 5933 |
| Language: | English |
| ACCESSION: | WOS:001159900803219 |
| DOI: | 10.1182/blood-2023-179609 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work